Funder: National Institutes of Health

Due Dates: April 23, 2025 (Letter of Intent) | May 7, 2025 (AIDS) | May 23, 2025 (Application) | August 25, 2025 (Letter of Intent) | September 7, 2025 (AIDS) | September 24, 2025 (Application) | January 7, 2026 (AIDS) | January 23, 2026 (Application) | May 7, 2026 (AIDS) | May 22, 2026 (Application) | September 7, 2026 (AIDS) | September 24, 2026 (Application)

Funding Amounts: Estimated $11M total in FY24; up to 4 awards; UG3 phase up to 2 years, UH3 phase up to 4 years, max 5 years total; budgets must reflect project needs.

Summary: Supports preclinical optimization and development of safe, effective, non-addictive small molecule and biologic therapeutics for pain, advancing candidates to IND and Phase I clinical testing.

Key Information: Strict milestone-driven, phased cooperative agreement; nonresponsive if missing required elements (milestones, TPP, IP plan, etc.); foreign organizations not eligible to apply.